What is Brief History of Exelixis Company?

Exelixis Bundle

Get Full Bundle:

	5 FORCES	$15	$10
	BCG	$15	$10
	CANVAS	$15	$10
	4P's MIX	$15	$10
	PESTLE	$15	$10
	SWOT	$15	$10

TOTAL:

ADD TO CART

How did Exelixis transform oncology treatment paradigms?

Founded in 1994 in South San Francisco, Exelixis evolved from gene-discovery roots into a commercial-stage oncology company after the 2012 FDA approval of cabozantinib, later Cabometyx, changing care for renal cell carcinoma and other solid tumors.

Exelixis built a multibillion-dollar franchise around Cabometyx, reported $1.8–$2.0 billion revenue in 2024, and held over $2.5 billion in cash and investments while advancing candidates like zanzalintinib (XL092).

Brief history: founded 1994; pivoted from systems-biology discovery to targeted oncology with global partnerships and broad clinical programs. See Exelixis Porter's Five Forces Analysis

Founded on November 15, 1994, Exelixis began as a genomics-driven biotech in South San Francisco, built by academic scientists aiming to translate conserved developmental pathways into human drug targets. The founding team combined expertise in neurobiology and molecular genetics to pursue functional genomics and target validation for oncology and other diseases.

Founding Story

Exelixis was launched by four academics who saw evolutionary biology as a pathway to new human therapeutics, initially licensing target discovery to big pharmas while building internal capabilities.

• Founded on November 15, 1994 in South San Francisco by Corey S. Goodman, Spyros Artavanis-Tsakonas, George A. Scangos, and Charles Zuker
• Business model focused on target identification, validation, and partnering with larger pharmaceutical companies
• Early funding combined venture capital, discovery alliances, and research contracts during the late-1990s genomics boom
• By early 2000s shifted toward advancing internal small-molecule programs, laying groundwork for later oncology pipeline

Founders leveraged model organisms such as Drosophila and C. elegans to exploit conserved signaling pathways; the company name references the Greek word exelixis meaning evolution, reflecting the scientific thesis. Early challenges included converting platform findings into clinical candidates amid the genomics hype, but strategic partnerships generated initial revenues and validated the Exelixis corporate background.

Between founding and 2005, Exelixis executed multiple discovery alliances and raised venture and strategic capital; leadership changes placed George A. Scangos in CEO roles early on to guide the transition to internal drug development. The shift enabled advancement toward clinical-stage programs that later defined Exelixis drug development milestones.

The founding narrative set the stage for the company's evolution of research and development strategy, moving from platform licensing to internal small-molecule development, which ultimately contributed to an oncology pipeline history centered on kinase inhibitors. For more detail, see Brief History of Exelixis.

Exelixis SWOT Analysis

• Complete SWOT Breakdown
• Fully Customizable
• Editable in Excel & Word
• Professional Formatting
• Investor-Ready Format

GET TEMPLATE ➔

Early Growth and Expansion charts Exelixis company history from a discovery-platform start to a commercial oncology company, driven by discovery collaborations, kinase programs leading to cabozantinib, and rapid headcount and facility growth in South San Francisco.

1998–2005: Platform to Product

Exelixis biography in these years shows multiple discovery deals with big pharma (including Bristol Myers Squibb) that provided cash runway and validation of its target-discovery platform. The company shifted focus from platform licensing to advancing kinase inhibitors into first-in-human trials, laying groundwork for cabozantinib-era programs while expanding facilities and growing headcount into the low hundreds in South San Francisco.

2006–2012: Validation and First Approval

A pivotal collaboration with GlaxoSmithKline validated Exelixis medicinal chemistry through MEK inhibitor programs; cabozantinib advanced into MET/VEGF clinical studies. In 2012 the FDA approved Cometriq for metastatic medullary thyroid cancer, marking Exelixis’s first commercial product and catalyzing ex-U.S. partnership deals to extend global reach.

2016–2020: Commercial Scale and Combinations

Cabometyx gained approvals in renal cell carcinoma and hepatocellular carcinoma; U.S. revenues grew from under $200 million annually to over $800 million as of peak years, supported by milestones and royalties. Facing PD-1/PD-L1 competition, Exelixis pursued combination strategies such as nivolumab plus cabozantinib in RCC to preserve market position.

2021–2024: Pipeline Diversification and Scale

The company expanded its oncology pipeline with candidates including zanzalintinib (XL092), XB002 (tissue-factor ADC), and XL102 (CDK7 inhibitor), and struck biotherapeutics partnerships (IconOVir, Cybrexa). By 2024 Cabometyx had treated tens of thousands of patients globally and Exelixis maintained a market capitalization generally in the range of $5–$8 billion, supported by operating cash flow and ongoing label-expansion efforts.

Key strategic moves—early big-pharma discovery deals, the GlaxoSmithKline MEK collaboration, FDA approval of Cometriq in 2012, and later ex-U.S. licensing—define the Exelixis corporate background and the evolution of Exelixis research and development strategy; see Mission, Vision & Core Values of Exelixis for organizational context.

Exelixis PESTLE Analysis

• Covers All 6 PESTLE Categories
• No Research Needed – Save Hours of Work
• Built by Experts, Trusted by Consultants
• Instant Download, Ready to Use
• 100% Editable, Fully Customizable

GET TEMPLATE ➔

Milestones, Innovations and Challenges: a concise review of Exelixis company history, highlighting regulatory wins, combo strategy, pipeline evolution and market pressures through 2024–2025.

Exelixis pioneered TKI + immuno-oncology combinations, notably translating CheckMate-9ER into durable first-line RCC practice; by 2024 this combo showed meaningful PFS and OS vs sunitinib. The company concurrently expanded modalities—next-gen TKIs and ADCs—while leveraging partnerships to scale global commercialization.

TKI + I/O Combination Leadership

CheckMate-9ER (nivolumab + cabozantinib) demonstrated statistically significant PFS and OS benefits, reshaping first-line RCC standards and maintaining market share amid competing regimens.

Multi-Indication Cabozantinib Franchise

Regulatory approvals from 2012 onward (MTC, RCC, HCC) created a versatile TKI backbone with commercial momentum, driving >$1.5 billion estimated annualized sales by 2024.

Next-Gen TKI Development

Zanzalintinib (XL092) was designed for improved kinase selectivity and tolerability versus cabozantinib and advanced into late-stage studies across RCC and other tumors.

ADC Platform Entry

XB002, an ADC targeting tissue factor, aligns with sector momentum in ADC dealmaking and represents modality diversification to reduce single-asset dependence.

Partner-Led Commercial Scale

Collaborations with Ipsen and Takeda provided co-funding, royalty streams and wider geographic reach, improving lifecycle management and revenue visibility.

Biomarker and Trial Design Focus

Shift toward biomarker-led designs and precision combos aimed to improve Phase II→III success probabilities amid industry attrition.

Competition among multiple TKI + I/O regimens (e.g., pembrolizumab + axitinib) created pricing and market-share pressures; payor scrutiny increased as annual oncology budgets tightened. Pipeline attrition and COVID-19 enrollment disruptions prompted program rationalizations and reallocation of capital toward higher-probability assets.

Competitive RCC Landscape

Multiple first-line TKI + I/O approvals intensified market competition, pressuring share and requiring sustained real-world effectiveness and access efforts.

Pricing and Payor Scrutiny

Heightened payer negotiations and value assessments increased demand for head-to-head or real-world evidence to justify price and formulary placement.

Pipeline Attrition

Some programs were discontinued or deprioritized, reflecting oncology Phase III success rates below industry averages and the need for selective investment.

COVID-19 Trial Disruption

Pandemic-related enrollment delays temporarily affected timelines and data-readout schedules for multiple studies.

Capital Allocation Pressure

Management emphasized capital discipline, redirecting resources to next-gen TKIs and ADCs to safeguard long-term growth.

Need for Biomarker Precision

Greater emphasis on predictive biomarkers was required to differentiate combinations and improve patient selection in crowded indications.

For additional context on market positioning and target segments, see Target Market of Exelixis.

Exelixis Business Model Canvas

• Complete 9-Block Business Model Canvas
• Effortlessly Communicate Your Business Strategy
• Investor-Ready BMC Format
• 100% Editable and Customizable
• Clear and Structured Layout

GET TEMPLATE ➔

Timeline and Future Outlook of the company traces its evolution from a 1994 research startup into a multi‑asset oncology firm, highlighting cabozantinib's commercialization, expanding pipeline through 2024–2025, and strategic plans to extend franchise value across RCC, HCC and other solid tumors.

Strategic priorities

Advance zanzalintinib toward potential registrational paths while accelerating the ADC program (XB002) and selective CDK inhibitor XL102 to build beyond cabo.

Combo and biomarker strategy

Pursue rational immuno‑oncology combinations and biomarker‑enriched studies to defend share in RCC/HCC and enter urothelial and endometrial indications.

Market dynamics

Shift to combination regimens, precision and ADC therapeutics continues; pricing pressure may be offset by value‑based outcomes and broader label utility supported by a strong balance sheet for BD&L.

Analyst expectations

Street models assume mid‑single to low‑double‑digit revenue CAGR through the mid‑2020s, with upside from positive pivotal data for XL092/ADC and additional partnerships; see Marketing Strategy of Exelixis for related analysis.

Exelixis Porter's Five Forces Analysis

• Covers All 5 Competitive Forces in Detail
• Structured for Consultants, Students, and Founders
• 100% Editable in Microsoft Word & Excel
• Instant Digital Download – Use Immediately
• Compatible with Mac & PC – Fully Unlocked

GET TEMPLATE ➔